AngioDynamics’ DIRECT clinical study features a comprehensive data collection strategy that will provide meaningful clinical information to healthcare professionals, support a regulatory indication ...

AngioDynamics shows how product mix shifts toward higher-margin Med Tech platforms are quietly reshaping earnings power ...

AngioDynamics (NASDAQ:ANGO) executives used a conference presentation hosted by J.P. Morgan to outline the company’s ...

Per the WARN notice, AngioDynamics cited “contract loss” as the reason for the upcoming layoffs of nonunion employees at its ...

Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.

AngioDynamics (ANGO) has been on a downward spiral lately with significant selling pressure. After declining 25% over the ...

AngioDynamics raised its full-year sales outlook after logging a higher top line in its fiscal second quarter, as the company scooped up market share from competitors. The medical-technology company ...

Shares of AngioDynamics (NASDAQ: ANGO) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came after the medical technology company announced its fiscal 2025 first-quarter ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

CEO Jim Clemmer highlighted strong Q3 performance with total revenue reaching $72 million, reflecting over 9% year-over-year growth. MedTech revenue grew by 22%, with continued success across ...

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, ...

AngioDynamics, a medical device manufacturer based in Latham, New York, has agreed to pay the federal government $12.5 million to resolve false claims allegations, according to the Times Union.